ANIK.OQ
Latest Trade
57.48USDChange
0.43(+0.75%)Volume
51,865Today's Range
-
58.6852 Week Range
-
75.54As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 57.05 |
|---|---|
Open | 57.08 |
Volume | 51,865 |
3M AVG Volume | 3.73 |
Today's High | 58.68 |
Today's Low | 57.08 |
52 Week High | 75.54 |
52 Week Low | 29.08 |
Shares Out (MIL) | 14.27 |
Market Cap (MIL) | 814.07 |
Forward P/E | 27.97 |
Dividend (Yield %) | -- |
Anika Therapeutics Reports Q3 EPS Of $0.64
Anika Therapeutic Reports Q2 EPS Of $0.67
Anika Therapeutics Entered Into An Accelerated Share Repurchase Agreement With Morgan Stanley & Co. Llc
Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company's therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company's ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.
Industry
Biotechnology & Drugs
Executive Leadership
Joseph G. Darling
President, Chief Executive Officer, Director
Sylvia Cheung
Chief Financial Officer, Treasurer, Secretary
Thomas Finnerty
Chief Human Resource Officer
Edward Ahn
Chief Technology and Strategy Officer
Joseph Lyon Bower
Independent Chairman of the Board
Price To Earnings (TTM) | 26.36 |
|---|---|
Price To Sales (TTM) | 7.28 |
Price To Book (MRQ) | 2.89 |
Price To Cash Flow (TTM) | 22.12 |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | 10.86 |
Return on Equity (TTM) | 10.48 |
* Q1 EARNINGS PER SHARE VIEW $0.16 -- THOMSON REUTERS I/B/E/S
* JOSEPH DARLING NAMED CEO AND DIRECTOR OF ANIKA THERAPEUTICS
* ANIKA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS
* ANIKA THERAPEUTICS ANNOUNCES STRATEGIC COLLABORATION WITH THE INSTITUTE OF INTEGRATIVE BIOLOGY AT THE UNIVERSITY OF LIVERPOOL TO DEVELOP AN INNOVATIVE THERAPY FOR OSTEOARTHRITIS Source text for Eikon: Further company coverage:
* ANIKA THERAPEUTICS EXPANDS STRATEGIC COLLABORATION WITH THE INSTITUTE FOR APPLIED LIFE SCIENCES (IALS) AT THE UNIVERSITY OF MASSACHUSETTS AMHERST TO DEVELOP INNOVATIVE THERAPY FOR RHEUMATOID ARTHRITIS Source text for Eikon: Further company coverage:
* ANIKA ANNOUNCES FDA 510(K) CLEARANCE FOR ITS INJECTABLE HA-BASED BONE REPAIR TREATMENT
* Q3 revenue rose 5 percent to $27.2 million Source text for Eikon: Further company coverage:
* Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis
* Anika announces the forthcoming appointment of Thomas M. Finnerty as chief human resources officer Source text for Eikon: Further company coverage:
* Anika announces regulatory approval for Monovisc® in Australia for the treatment of pain associated with osteoarthritis of all synovial joints
* Kayne anderson rudnick investment management llc reports 11.49 percent passive stake in anika therapeutics inc as of august 08, 2017 - sec filing Source text - (http://bit.ly/2fqZxZ8) Further company coverage:
* Anika therapeutics - co's ceo dr. Charles h. Sherwood who served as president, plans to transition role to darling, while continuing tenure as ceo Source text for Eikon: Further company coverage:
* Anika announces regulatory approval for Monovisc in India for the treatment of pain associated with osteoarthritis of all synovial joints Source text for Eikon: Further company coverage:
* Anika announces $5 million milestone payment from U.S. Commercial sales of Monovisc
* Anika announces first patient enrolled in supplemental phase III trial of CINGAL for the treatment of knee pain associated with osteoarthritis
* Q1 earnings per share view $0.38 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:
* Anika reports fourth quarter and full year 2016 financial results
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.